Targeting AML through DR4 with a novel variant of rhTRAIL

Despite progress in the treatment of acute myelogenous leukaemia (AML) the outcome often remains poor. Tumour necrosis factor related apoptosis‐inducing ligand (TRAIL) is a promising therapeutic agent in many different types of tumours, but AML cells are relatively insensitive to TRAIL‐induced apopt...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of cellular and molecular medicine 2011-10, Vol.15 (10), p.2216-2231
Hauptverfasser:	Szegezdi, Eva, Reis, Carlos R., Sloot, Almer M. van der, Natoni, Alessandro, O’Reilly, Aoife, Reeve, Janice, Cool, Robbert H., O’Dwyer, Michael, Knapper, Steven, Serrano, Luis, Quax, Wim J., Samali, Afshin
Format:	Artikel
Sprache:	eng
Schlagworte:	acute myelogenous leukaemia (AML) Adult Aged Aged, 80 and over Apoptosis Cell death Cell Line, Tumor death receptor 4 (DR4) DR5 Drug development Epidermis - cytology Female Fibroblasts Hematology Humans Imidazoles - pharmacology Keratinocytes - cytology Leukemia Leukemia, Myeloid, Acute - drug therapy Leukocyte Count Male Membrane Potentials Middle Aged Penicillin primary AML blast Quinoxalines - pharmacology Receptors, TNF-Related Apoptosis-Inducing Ligand - genetics Receptors, TNF-Related Apoptosis-Inducing Ligand - metabolism receptor‐selective TRAIL variant Sensors Side effects Sodium TNF-Related Apoptosis-Inducing Ligand - therapeutic use TRAIL protein tumour necrosis factor‐related apoptosis‐inducing ligand (TRAIL)
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!